Nebulised amphotericin B to eradicate Candida colonisation from the respiratory tract in critically ill patients receiving selective digestive decontamination: A cohort study

Critical Care

Volumn 17, Issue 5, 2013, Pages

  Ong, David S Y ^a   MC Klein Klouwenberg, Peter ^a   Spitoni, Cristian ^a,b   Bonten, Marc J M ^a   Cremer, Olaf L ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CORTICOSTEROID; ANTIFUNGAL AGENT;

ADULT; AGE; ARTICLE; ASEPSIS; CANDIDA; CANDIDEMIA; CLINICAL PROTOCOL; COHORT ANALYSIS; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DRUG EFFICACY; ERADICATION THERAPY; FEMALE; FUNGAL COLONIZATION; HUMAN; INCIDENCE; LENGTH OF STAY; LOWER RESPIRATORY TRACT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PNEUMONIA; PRIORITY JOURNAL; SPUTUM CULTURE; VENTILATED PATIENT; AGED; CANDIDIASIS; CRITICAL ILLNESS; DIGESTIVE SYSTEM; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; MICROBIOLOGY; MIDDLE AGED; NEBULIZER; NETHERLANDS; PNEUMONIA, VENTILATOR-ASSOCIATED; PROCEDURES; RESPIRATORY SYSTEM; WASTE MANAGEMENT;

ADMINISTRATION, INHALATION; ADULT; AGED; AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; CRITICAL ILLNESS; DECONTAMINATION; DIGESTIVE SYSTEM; FEMALE; HUMANS; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; NETHERLANDS; PNEUMONIA, VENTILATOR-ASSOCIATED; RESPIRATORY SYSTEM;

EID: 84885355693     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc13056     Document Type: Article

References (31)

1. Azoulay E, Timsit JF, Tafflet M, de Lassence A, Darmon M, Zahar JR, Adrie C, Garrouste-Orgeas M, Cohen Y, Mourvillier B, Schlemmer B. Candida colonization of the respiratory tract and subsequent pseudomonas ventilator-associated pneumonia. Chest 2006, 129:110-117. 10.1378/chest.129.1.110, 16424420.
2. Delisle MS, Williamson DR, Perreault MM, Albert M, Jiang X, Heyland DK. The clinical significance of Candida colonization of respiratory tract secretions in critically ill patients. J Crit Care 2008, 23:11-17. 10.1016/j.jcrc.2008.01.005, 18359416.
3. Hamet M, Pavon A, Dalle F, Pechinot A, Prin S, Quenot JP, Charles PE. Candida spp. airway colonization could promote antibiotic-resistant bacteria selection in patients with suspected ventilator-associated pneumonia. Intensive Care Med 2012, 38:1272-1279. 10.1007/s00134-012-2584-2, 22699790.
4. Olaechea PM, Palomar M, Leon-Gil C, Alvarez-Lerma F, Jorda R, Nolla-Salas J, León-Regidor MA, et al. Economic impact of Candida colonization and Candida infection in the critically ill patient. Eur J Clin Microbiol Infect Dis 2004, 23:323-330. 10.1007/s10096-004-1104-x, 15024623.
5. Ricard JD, Roux D. Candida pneumonia in the ICU: myth or reality?. Intensive Care Med 2009, 35:1500-1502. 10.1007/s00134-009-1563-8, 19562321.
6. Meersseman W, Lagrou K, Spriet I, Maertens J, Verbeken E, Peetermans WE, Van Wijngaerden E. Significance of the isolation of Candida species from airway samples in critically ill patients: a prospective, autopsy study. Intensive Care Med 2009, 35:1526-1531. 10.1007/s00134-009-1482-8, 19357832.
7. El-Azizi MA, Starks SE, Khardori N. Interactions of Candida albicans with other Candida spp. and bacteria in the biofilms. J Appl Microbiol 2004, 96:1067-1073. 10.1111/j.1365-2672.2004.02213.x, 15078523.
8. Ricard JD, Roux D. Candida colonization in ventilated ICU patients: no longer a bystander!. Intensive Care Med 2012, 38:1243-1245. 10.1007/s00134-012-2587-z, 22699791.
9. Nseir S, Jozefowicz E, Cavestri B, Sendid B, Di PC, Dewavrin F, Favory R, Roussel-Delvallez M, Durocher A. Impact of antifungal treatment on Candida-Pseudomonas interaction: a preliminary retrospective case-control study. Intensive Care Med 2007, 33:137-142. 10.1007/s00134-006-0422-0, 17115135.
10. Roux D, Gaudry S, Dreyfuss D, El-Benna J, de Prost N, Denamur E, Saumon G, Ricard JD. Candida albicans impairs macrophage function and facilitates Pseudomonas aeruginosa pneumonia in rat. Crit Care Med 2009, 37:1062-1067. 10.1097/CCM.0b013e31819629d2, 19237918.
11. Lam SW, Eschenauer GA, Carver PL. Evolving role of early antifungals in the adult intensive care unit. Crit Care Med 2009, 37:1580-1593. 10.1097/CCM.0b013e31819dec9b, 19325484.
12. de Smet AM, Kluytmans JA, Cooper BS, Mascini EM, Benus RF, van der Werf TS, van der Hoeven JG, Pickkers P, Bogaers-Hofman D, van der Meer NJ, Bernards AT, Kuijper EJ, Joore JC, Leverstein-van Hall MA, Bindels AJ, Jansz AR, Wesselink RM, de Jongh BM, Dennesen PJ, van Asselt GJ, te Velde LF, Frenay IH, Kaasjager K, Bosch FH, van Iterson M, Thijsen SF, Kluge GH, Pauw W, de Vries JW, Kaan JA, et al. Decontamination of the digestive tract and oropharynx in ICU patients. N Engl J Med 2009, 360:20-31. 10.1056/NEJMoa0800394, 19118302.
13. Shintani AK, Girard TD, Eden SK, Arbogast PG, Moons KG, Ely EW. Immortal time bias in critical care research: application of time-varying Cox regression for observational cohort studies. Crit Care Med 2009, 37:2939-2945. 10.1097/CCM.0b013e3181b7fbbb, 3365557, 19770737.
14. Suissa S. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies. Am J Respir Crit Care Med 2003, 168:49-53. 10.1164/rccm.200210-1231OC, 12663327.
15. Simon R, Makuch RW. A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. Stat Med 1984, 3:35-44. 10.1002/sim.4780030106, 6729287.
16. Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Stat Med 2007, 26:2389-2430. 10.1002/sim.2712, 17031868.
17. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008, 36:309-332. 10.1016/j.ajic.2008.03.002, 18538699.
18. Klein Klouwenberg PM, Ong DS, Bos LD, de Beer FM, van Hooijdonk RT, Huson MA, Straat M, van Vught LA, Wieske L, Horn J, Schultz MJ, van der Poll T, Bonten MJ, Cremer OL. Interobserver agreement of centers for disease control and prevention criteria for classifying infections in critically Ill patients. Crit Care Med 2013, 41:2373-2378. 10.1097/CCM.0b013e3182923712, 23921277.
19. de Jonge E, Schultz MJ, Spanjaard L, Bossuyt PM, Vroom MB, Dankert J, Kesecioglu J. Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial. Lancet 2003, 362:1011-1016. 10.1016/S0140-6736(03)14409-1, 14522530.
20. Dummer JS, Lazariashvilli N, Barnes J, Ninan M, Milstone AP. A survey of anti-fungal management in lung transplantation. J Heart Lung Transplant 2004, 23:1376-1381. 10.1016/j.healun.2003.09.028, 15607667.
21. Koo S, Kubiak DW, Issa NC, Dietzek A, Boukedes S, Camp PC, Goldberg HJ, Baden LR, Fuhlbrigge AL, Marty FM. A targeted peritransplant antifungal strategy for the prevention of invasive fungal disease after lung transplantation: a sequential cohort analysis. Transplantation 2012, 94:281-286.
22. Monforte V, Ussetti P, Lopez R, Gavalda J, Bravo C, de Pablo A, Pou L, Pahissa A, Morell F, Román A. Nebulized liposomal amphotericin B prophylaxis for Aspergillus infection in lung transplantation: pharmacokinetics and safety. J Heart Lung Transplant 2009, 28:170-175. 10.1016/j.healun.2008.11.004, 19201343.
23. Dhand R. The role of aerosolized antimicrobials in the treatment of ventilator-associated pneumonia. Respir Care 2007, 52:866-884.
24. Dolovich MB, Dhand R. Aerosol drug delivery: developments in device design and clinical use. Lancet 2011, 377:1032-1045. 10.1016/S0140-6736(10)60926-9, 21036392.
25. Kuiper L, Ruijgrok EJ. A review on the clinical use of inhaled amphotericin B. J Aerosol Med Pulm Drug Deliv 2009, 22:213-227. 10.1089/jamp.2008.0715, 19466905.
26. Drew RH, Dodds AE, Benjamin DK, Duane DR, Palmer SM, Perfect JR. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation 2004, 77:232-237. 10.1097/01.TP.0000101516.08327.A9, 14742987.
27. Dubois J, Bartter T, Gryn J, Pratter MR. The physiologic effects of inhaled amphotericin B. Chest 1995, 108:750-753. 10.1378/chest.108.3.750, 7656628.
28. Lowry CM, Marty FM, Vargas SO, Lee JT, Fiumara K, Deykin A, et al. Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: a retrospective study. Transpl Infect Dis 2007, 9:121-125. 10.1111/j.1399-3062.2007.00209.x, 17461997.
29. Myers SE, Devine SM, Topper RL, Ondrey M, Chandler C, O'Toole K, Williams SF, Larson RA, Geller RB. A pilot study of prophylactic aerosolized amphotericin B in patients at risk for prolonged neutropenia. Leuk Lymphoma 1992, 8:229-233. 10.3109/10428199209054909, 1490149.
30. Bergmans DC, Bonten MJ, Gaillard CA, Paling JC, van der Geest S, van Tiel FH, Beysens AJ, de Leeuw PW, Stobberingh EE. Prevention of ventilator-associated pneumonia by oral decontamination: a prospective, randomized, double-blind, placebo-controlled study. Am J Respir Crit Care Med 2001, 164:382-388. 10.1164/ajrccm.164.3.2005003, 11500337.
31. Levesque LE, Hanley JA, Kezouh A, Suissa S. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ 2010, 340:b5087. 10.1136/bmj.b5087, 20228141.